Virological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia

dc.contributor.authorFeyissa, Bekelech Bayou
dc.contributor.authorSisay, Abay
dc.contributor.authorDavids, Eugene Lee
dc.contributor.authorYalew, Anteneh; Setswe, Geoffrey
dc.date.accessioned2026-03-20T11:58:42Z
dc.date.available2026-03-20T11:58:42Z
dc.date.issued2026-02
dc.descriptionDATA AVAILABILITY : All relevant data are within the paper and its Supporting information files. SUPPORTING INFORMATION FIGURE S1. Concurrent mixed cohort research design used in this study. FIGURE S2. Infographic depicting the overall summary of defining virological failure in the research process. FIGURE S3. A time range by which the patients developed OI while on second-line ART in Addis Ababa, Ethiopia.
dc.description.abstractBACKGROUND : Virological failure (VF) presents significant challenges in the emergence of drug resistance, and elevated risk of transmission, higher mortality rates, and a diminished quality of life. Various factors contribute to VF, but documented information on this issue is lacking in Ethiopia. Therefore, this study aimed to assess the prevalence of VF and identify the risk factors among people living with HIV who are on second-line antiretroviral treatment (ART). METHODS : A concurrent mixed-method study using quantitative and qualitative data was conducted at selected hospitals in Addis Ababa, Ethiopia. The analysis was conducted using SPSS version 28, Stata version 18.5, and R for quantitative data and thematic analysis with Atlas.ti version 24 software was used for qualitative data. RESULT : Among 369 adults living with HIV taking second-line ART enrolled in the study, 191 (52%) were male with a median age of 44 years. The prevalence of VF was 55 (14.9%, 95% CI: 11, 19), with an incidence density of 27.2 per 10,000 person months (95% CI 21.1, 35.5). Lost to follow-up significantly increased VF risk [AHR: 2.52 (95% CI: 1.35, 4.69, p-value: 0.004)]. Patients transferred from other health facilities were two times at higher risk of VF compared to those receiving ART at the same facility [AHR: 1.97 (95% CI: 1.07, 3-64, p-value: 0.029)]. Likewise, clients with a history of regimen change were at a higher risk of VF [AHR = 2.05, (95% CI: 1.08, 3.88, p-value = 0.027)]. The qualitative data also supported these findings. CONCLUSION : This study underscores the need for improved ART adherence and consistent care to reduce virological failure in PLHIV to improve the quality of life.
dc.description.departmentPsychology
dc.description.librarianhj2026
dc.description.sdgSDG-03: Good health and well-being
dc.description.sponsorshipAddis Ababa University supported the research data collection expenses and support from the University of South Africa (UNISA) through the Bursary System.
dc.description.urihttps://journals.plos.org/plosone/
dc.identifier.citationFeyissa, B.B., Sisay, A., Davids, E.L., Yalew, A. & Setswe, G. (2026) Virological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia. PLoS One 21(2): e0330581: 1-21. https://doi.org/10.1371/journal.pone.0330581.
dc.identifier.issn1932-6203 (online)
dc.identifier.other10.1371/journal.pone.0330581
dc.identifier.urihttp://hdl.handle.net/2263/109103
dc.language.isoen
dc.publisherPublic Library of Science
dc.rights© 2026 Feyissa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
dc.subjectVirological failure
dc.subjectPeople living with HIV (PLHIV)
dc.subjectAntiretroviral therapy (ART)
dc.subjectDrug resistance
dc.subjectElevated risk of transmission
dc.subjectMortality rates
dc.subjectQuality of life (QoL)
dc.subjectEthiopia
dc.titleVirological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia
dc.typeArticle

Files

Original bundle

Now showing 1 - 4 of 4
Loading...
Thumbnail Image
Name:
Feyissa_Virological_2026.pdf
Size:
952.05 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Feyissa_VirologicalFigS1_2026.pdf
Size:
81.1 KB
Format:
Adobe Portable Document Format
Description:
Figure S1
Loading...
Thumbnail Image
Name:
Feyissa_VirologicalFigS2_2026.pdf
Size:
111.97 KB
Format:
Adobe Portable Document Format
Description:
Figure S2
Loading...
Thumbnail Image
Name:
Feyissa_VirologicalFigS3_2026.pdf
Size:
92.08 KB
Format:
Adobe Portable Document Format
Description:
Figure S3

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: